Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
The American Journal of Medicine
|
December 27, 2011
Surprise under the sleeve
Agnes Mwakingwe, Jemilat Badamas, Jennifer Cheng, et al.
The American Journal of Medicine
|
June 10, 2015
Bigger Foot: Kaposi's Sarcoma
Rekha R Rapaka, Max Fischer, Thomas E Finucane, et al.
Human Vaccines & Immunotherapeutics
|
November 15, 2023
Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
Agnes Mwakingwe-Omari, Nicolas Lecrenier, Abdi Naficy, et al.
The Journal of Infectious Diseases
|
October 9, 2009
Noninvasive real-time monitoring of liver-stage development of bioluminescent Plasmodium parasites
Agnes Mwakingwe, Li-Min Ting, Sarah Hochman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 26, 2026
Age-Specific Risk of Herpes Zoster in Adults Aged ≥18 Years With Comorbid Conditions-A Retrospective Cohort Study in the United States
Rachel A Cohen, Driss Oraichi, Agnes Mwakingwe-Omari, et al.
Vaccine
|
February 9, 2025
Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial
Abdi Naficy, Yashpal Chugh, Mohd Tariq, et al.
Open Forum Infectious Diseases
|
April 10, 2026
Age-specific Risk of Herpes Zoster in Immunocompetent Adults ≥18 Years-of-age-A Retrospective Cohort Study in the United States
Rachel A Cohen, Driss Oraichi, Agnes Mwakingwe-Omari, et al.
Human Vaccines & Immunotherapeutics
|
March 21, 2024
No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial
Abdi Naficy, Adrienne Kuxhausen, Harry Seifert, et al.
The Journal of Infection
|
December 29, 2021
The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial
Ji-Young Min, Agnes Mwakingwe-Omari, Megan Riley, et al.
The Journal of Infectious Diseases
|
August 12, 2025
Real-world effectiveness of the adjuvanted recombinant zoster vaccine in ≥50-year-old adults with autoimmune diseases
Dagna Constenla, Germain Lonnet, Emmanuel Aris, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
The American Journal of Medicine
|
December 27, 2011
Surprise under the sleeve
Agnes Mwakingwe, Jemilat Badamas, Jennifer Cheng, et al.
The American Journal of Medicine
|
June 10, 2015
Bigger Foot: Kaposi's Sarcoma
Rekha R Rapaka, Max Fischer, Thomas E Finucane, et al.
Human Vaccines & Immunotherapeutics
|
November 15, 2023
Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
Agnes Mwakingwe-Omari, Nicolas Lecrenier, Abdi Naficy, et al.
The Journal of Infectious Diseases
|
October 9, 2009
Noninvasive real-time monitoring of liver-stage development of bioluminescent Plasmodium parasites
Agnes Mwakingwe, Li-Min Ting, Sarah Hochman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 26, 2026
Age-Specific Risk of Herpes Zoster in Adults Aged ≥18 Years With Comorbid Conditions-A Retrospective Cohort Study in the United States
Rachel A Cohen, Driss Oraichi, Agnes Mwakingwe-Omari, et al.
Vaccine
|
February 9, 2025
Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial
Abdi Naficy, Yashpal Chugh, Mohd Tariq, et al.
Open Forum Infectious Diseases
|
April 10, 2026
Age-specific Risk of Herpes Zoster in Immunocompetent Adults ≥18 Years-of-age-A Retrospective Cohort Study in the United States
Rachel A Cohen, Driss Oraichi, Agnes Mwakingwe-Omari, et al.
Human Vaccines & Immunotherapeutics
|
March 21, 2024
No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial
Abdi Naficy, Adrienne Kuxhausen, Harry Seifert, et al.
The Journal of Infection
|
December 29, 2021
The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial
Ji-Young Min, Agnes Mwakingwe-Omari, Megan Riley, et al.
The Journal of Infectious Diseases
|
August 12, 2025
Real-world effectiveness of the adjuvanted recombinant zoster vaccine in ≥50-year-old adults with autoimmune diseases
Dagna Constenla, Germain Lonnet, Emmanuel Aris, et al.
Page
of 3